iBio, Inc. IBIO 深 滬
等待開盤 06-25 09:30:00 美东时间
1.62
-0.030
-1.82%
華盛通- 最 高1.69
- 今 開1.68
- 成交量 40.21万股
- 最 低 1.62
- 昨 收 1.65
- 總市值 8047.93万
- 52周最高 3.82
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 0.5562
- 委 比 97.16%
- 總股本 4967.86万
- 歷史最高 17400.00
- 量 比 0.37
- 振 幅 4.24%
- 歷史最低 0.5562
- 每 手 1
- 風險率 0.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
iBio to Participate in Upcoming Healthcare Investor Conferences
iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing therapies for obesity, cardiometabolic, and cardiopulmonary diseases, announced that its CEO and CSO, Martin Brenner, DVM, Ph.D., and CFO, Felipe Duran, will participate in the Jefferies Global Healthcare Conference on June 4, 2026, in New York, and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference in Boston from July 14–15, 2026. The Jefferies prese...
06-02 20:01
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial
iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first
06-02 19:04
IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar
Ibio Inc ($IBIO) announced an update on their ongoing clinical study. The Phase...
05-30 00:35
华盛早报 | 特朗普持仓大曝光！大额买入英伟达、苹果；SpaceX招股说明书据悉最快下周披露！
特朗普持仓大曝光！大额买入英伟达、苹果等；H200“松绑”落地！英伟达大涨逾4%创新高，联想已证实获准分销；SpaceX招股书最快下周披露！估值高达1.25万亿美元>>
05-15 08:26
华盛早报 | 恒科今日反攻？阿里、腾讯ADR绩后狂飙；党派分歧“史无前例”！沃什出任美联储主席
恒科今日反攻？阿里美股大涨逾8%，腾讯ADR涨近5%！双双上调AI资本开支；党派分歧“史无前例”！沃什出任美联储主席；半导体双雄中芯国际、华虹半导体即将放榜>>
05-14 08:33
港股早知道 | 中国AI用电料大增！算电协同受关注；阿里巴巴Q4云智能集团收入同比增38%
中国AI用电料大增！算电协同受关注；阿里巴巴Q4云智能集团收入同比增38%；腾讯Q1净利润同比增长21%>>
05-14 08:22
iBio Q3 EPS $(0.07) Misses $(0.06) Estimate
iBio (AMEX:IBIO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 85.71 percent increase over losses of $(0.49) per share from the same
05-13 05:07
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
iBio, Inc. has appointed Elizabeth Stoner, M.D., M.S., as an independent member of its Board of Directors and to the Compensation Committee, following Eef Schimmelpennink's departure. Dr. Stoner brings over 35 years of experience in biotech research, development, and leadership, including roles at MPM BioImpact, Semma Therapeutics, and Rhythm Pharmaceuticals. Her expertise will support iBio’s first human clinical trial for treatments targeting ob...
05-08 11:15
